.Merck beats incomes desires, increases purchases outlook on strong demand for leading medications like Keytruda CNBCMerck & Co. (MRK US) Trumps Income Projections as Keytruda Sales Growth BloombergMerck Stock: Pharma Giant Posts Tough Outcomes, However Outlook Tumbles Short Real estate investor's Company DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck defeats earnings as well as sales requirements in the middle of Keytruda strength, but supplies blended full-year overview MarketWatch.